Bristol Myers Squibb stock gains on Zenbexus and strong Q2
Published on 08/21/2026 at 22:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb Company (US1078421011) is drawing investor attention after Zenbexus won accelerated FDA approval on August 13, 2026, while second-quarter 2026 revenue reached $12.97 billion and EPS came in at $2.04.
The latest quarter also showed a $0.44 EPS beat versus the $1.60 consensus and revenue that topped the $11.74 billion estimate, giving the shares a fresh earnings-and-regulatory backdrop.
Approval adds a new catalyst
Quiver Quantitative said the August 13 approval for Zenbexus in multiple myeloma is the most likely driver of the recent move, alongside the late-July earnings report and higher full-year guidance. The company also lifted its 2026 revenue outlook to $49.0 billion to $50.0 billion and kept non-GAAP EPS guidance at $6.75 to $7.00.
That combination matters because it ties a new commercial asset to a stronger profit and sales framework. Revenue growth of 5.7 percent year over year in the second quarter showed the base business is still expanding even before any full contribution from the new approval.
Analysts are split
MarketBeat's consensus view shows 25 analyst ratings with a Moderate Buy label, a $66.06 average target, and a current extended-hours quote of $65.88 as of August 20, 2026 at 6:44 p.m. ET. The same page lists a 52-week range from $42.52 to $72.50, which leaves the stock close to the upper half of that band.
That setup leaves limited distance to consensus while still reflecting the improved guidance story. A recent update also shows several firms lifting or reiterating targets into the $70 to $75 range, while one large bank kept a $64 target, underscoring a divided view on valuation.
Zenbexus is the product angle
Zenbexus is now the key product reference point for Bristol Myers Squibb after the August 13 FDA decision, because it gives the company another growth lever in multiple myeloma. For investors, the new approval is more important than the usual pipeline talk because it is tied to an actual commercial event and not just development-stage optionality.
Shares near the upper band
At $65.88 in extended trading on August 20, 2026, Bristol Myers Squibb sits above the midpoint of its $42.52 to $72.50 range and just below the $66.06 consensus target. That keeps the stock in a zone where earnings execution and Zenbexus uptake can matter as much as broad market sentiment.
Fact box
Company: Bristol-Myers Squibb Company
ISIN: US1078421011
Ticker: BMY
Exchange: NYSE
Price (as of August 20, 2026, 6:44 p.m. ET): $65.88 USD
Market cap: $133.88 billion
Sector / Industry: Health Care / Biotechnology
Index membership: S&P 500
Next earnings date: November 2026
More on Bristol Myers Squibb stock
Bristol Myers Squibb's second-quarter 2026 report showed $12.97 billion in revenue, $2.04 in EPS, and a 5.7 percent year-over-year sales increase, while full-year 2026 guidance now points to $49.0 billion to $50.0 billion in revenue and $6.75 to $7.00 in non-GAAP EPS.
